Review



rabbit polyclonal anti rrm2 antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Proteintech rabbit polyclonal anti rrm2 antibody
    Figure 5. Immunohistochemical analysis of <t>RRM2,</t> FTCD, CYP2C9, and ATP6V1C1 in adjacent non-cancerous and cancerous tissues from HCC patients (original magnification, ×200). (a) <t>RRM2</t> expression in adjacent non-cancerous tissue. (b) RRM2 expression in cancerous tissue. (c) FTCD expression in adjacent non- cancerous tissue. (d) FTCD expression in cancerous tissue. (e) CYP2C9 expression in adjacent non-cancerous tissue. (f) CYP2C9 expression in cancerous tissue. (g) ATP6V1C1 expression in adjacent non-cancerous tissue. (h) ATP6V1C1 expression in cancerous tissue.
    Rabbit Polyclonal Anti Rrm2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 49 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti rrm2 antibody/product/Proteintech
    Average 94 stars, based on 49 article reviews
    rabbit polyclonal anti rrm2 antibody - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma."

    Article Title: A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma.

    Journal: Bioengineered

    doi: 10.1080/21655979.2020.1866303

    Figure 5. Immunohistochemical analysis of RRM2, FTCD, CYP2C9, and ATP6V1C1 in adjacent non-cancerous and cancerous tissues from HCC patients (original magnification, ×200). (a) RRM2 expression in adjacent non-cancerous tissue. (b) RRM2 expression in cancerous tissue. (c) FTCD expression in adjacent non- cancerous tissue. (d) FTCD expression in cancerous tissue. (e) CYP2C9 expression in adjacent non-cancerous tissue. (f) CYP2C9 expression in cancerous tissue. (g) ATP6V1C1 expression in adjacent non-cancerous tissue. (h) ATP6V1C1 expression in cancerous tissue.
    Figure Legend Snippet: Figure 5. Immunohistochemical analysis of RRM2, FTCD, CYP2C9, and ATP6V1C1 in adjacent non-cancerous and cancerous tissues from HCC patients (original magnification, ×200). (a) RRM2 expression in adjacent non-cancerous tissue. (b) RRM2 expression in cancerous tissue. (c) FTCD expression in adjacent non- cancerous tissue. (d) FTCD expression in cancerous tissue. (e) CYP2C9 expression in adjacent non-cancerous tissue. (f) CYP2C9 expression in cancerous tissue. (g) ATP6V1C1 expression in adjacent non-cancerous tissue. (h) ATP6V1C1 expression in cancerous tissue.

    Techniques Used: Immunohistochemical staining, Expressing



    Similar Products

    93
    Novus Biologicals rabbit polyclonal primary antibody against rrm2
    Clinical and pathological characteristics of patient cohort
    Rabbit Polyclonal Primary Antibody Against Rrm2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal primary antibody against rrm2/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    rabbit polyclonal primary antibody against rrm2 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    94
    Proteintech rabbit polyclonal anti rrm2 antibody
    Figure 5. Immunohistochemical analysis of <t>RRM2,</t> FTCD, CYP2C9, and ATP6V1C1 in adjacent non-cancerous and cancerous tissues from HCC patients (original magnification, ×200). (a) <t>RRM2</t> expression in adjacent non-cancerous tissue. (b) RRM2 expression in cancerous tissue. (c) FTCD expression in adjacent non- cancerous tissue. (d) FTCD expression in cancerous tissue. (e) CYP2C9 expression in adjacent non-cancerous tissue. (f) CYP2C9 expression in cancerous tissue. (g) ATP6V1C1 expression in adjacent non-cancerous tissue. (h) ATP6V1C1 expression in cancerous tissue.
    Rabbit Polyclonal Anti Rrm2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti rrm2 antibody/product/Proteintech
    Average 94 stars, based on 1 article reviews
    rabbit polyclonal anti rrm2 antibody - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    Image Search Results


    Clinical and pathological characteristics of patient cohort

    Journal: Diagnostic Pathology

    Article Title: RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance

    doi: 10.1186/s13000-021-01174-4

    Figure Lengend Snippet: Clinical and pathological characteristics of patient cohort

    Article Snippet: Rabbit polyclonal primary antibody against RRM2 (NBP1–31661), obtained from NOVUS Biological, Centennial, Co 80,112 USA was used at a dilution rate of 1:50. (DAB) was used as a chromogen, after that, hematoxylin was applied for counterstaining.

    Techniques:

    Intense RRM2 expression in cancer breast ×200

    Journal: Diagnostic Pathology

    Article Title: RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance

    doi: 10.1186/s13000-021-01174-4

    Figure Lengend Snippet: Intense RRM2 expression in cancer breast ×200

    Article Snippet: Rabbit polyclonal primary antibody against RRM2 (NBP1–31661), obtained from NOVUS Biological, Centennial, Co 80,112 USA was used at a dilution rate of 1:50. (DAB) was used as a chromogen, after that, hematoxylin was applied for counterstaining.

    Techniques: Expressing

    Correlation between  RRM2  protein expression and other clinicopathological variables

    Journal: Diagnostic Pathology

    Article Title: RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance

    doi: 10.1186/s13000-021-01174-4

    Figure Lengend Snippet: Correlation between RRM2 protein expression and other clinicopathological variables

    Article Snippet: Rabbit polyclonal primary antibody against RRM2 (NBP1–31661), obtained from NOVUS Biological, Centennial, Co 80,112 USA was used at a dilution rate of 1:50. (DAB) was used as a chromogen, after that, hematoxylin was applied for counterstaining.

    Techniques: Expressing

    Kaplan-Meier disease free survival for  RRM2  score in whole series

    Journal: Diagnostic Pathology

    Article Title: RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance

    doi: 10.1186/s13000-021-01174-4

    Figure Lengend Snippet: Kaplan-Meier disease free survival for RRM2 score in whole series

    Article Snippet: Rabbit polyclonal primary antibody against RRM2 (NBP1–31661), obtained from NOVUS Biological, Centennial, Co 80,112 USA was used at a dilution rate of 1:50. (DAB) was used as a chromogen, after that, hematoxylin was applied for counterstaining.

    Techniques:

    Kaplan-Meier DFS for  RRM2  score in ER positive group

    Journal: Diagnostic Pathology

    Article Title: RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance

    doi: 10.1186/s13000-021-01174-4

    Figure Lengend Snippet: Kaplan-Meier DFS for RRM2 score in ER positive group

    Article Snippet: Rabbit polyclonal primary antibody against RRM2 (NBP1–31661), obtained from NOVUS Biological, Centennial, Co 80,112 USA was used at a dilution rate of 1:50. (DAB) was used as a chromogen, after that, hematoxylin was applied for counterstaining.

    Techniques:

    Figure 5. Immunohistochemical analysis of RRM2, FTCD, CYP2C9, and ATP6V1C1 in adjacent non-cancerous and cancerous tissues from HCC patients (original magnification, ×200). (a) RRM2 expression in adjacent non-cancerous tissue. (b) RRM2 expression in cancerous tissue. (c) FTCD expression in adjacent non- cancerous tissue. (d) FTCD expression in cancerous tissue. (e) CYP2C9 expression in adjacent non-cancerous tissue. (f) CYP2C9 expression in cancerous tissue. (g) ATP6V1C1 expression in adjacent non-cancerous tissue. (h) ATP6V1C1 expression in cancerous tissue.

    Journal: Bioengineered

    Article Title: A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma.

    doi: 10.1080/21655979.2020.1866303

    Figure Lengend Snippet: Figure 5. Immunohistochemical analysis of RRM2, FTCD, CYP2C9, and ATP6V1C1 in adjacent non-cancerous and cancerous tissues from HCC patients (original magnification, ×200). (a) RRM2 expression in adjacent non-cancerous tissue. (b) RRM2 expression in cancerous tissue. (c) FTCD expression in adjacent non- cancerous tissue. (d) FTCD expression in cancerous tissue. (e) CYP2C9 expression in adjacent non-cancerous tissue. (f) CYP2C9 expression in cancerous tissue. (g) ATP6V1C1 expression in adjacent non-cancerous tissue. (h) ATP6V1C1 expression in cancerous tissue.

    Article Snippet: Then, sections were incubated with primary rabbit polyclonal anti-RRM2 antibody (1:50, 11661-1-AP, Proteintech, China), primary rabbit polyclonal anti-FTCD antibody (1:50, 21959-1-AP, Proteintech, China), primary rabbit polyclonal antiCYP2C9 antibody (1:200, 16546-1-AP, Proteintech, China), and primary rabbit polyclonal antiATP6V1C1 antibody (1:50, 16054-1-AP, Proteintech, China) at 4 °C overnight, followed by an incubation with the corresponding secondary antibodies at 37 °C for 30 minutes.

    Techniques: Immunohistochemical staining, Expressing